StreetAlpha.app
Home › Stocks › IMCR

Immunocore Holdings plc (IMCR)

Healthcare
$27.81
▼ −3.70%
LAST CLOSE · NOV 17

Immunocore develops biological product candidates based on its ImmTAX platform, from Oxfordshire, United Kingdom. It last closed at $27.81 on Nov 17, down 3.70% on the day. The average 12-month price target from 3 analysts is $57.33 (+106.2% from the last close), with a high of $80.00 and a low of $42.00. Analyst consensus is Buy, based on the latest ratings from 3 firms (2 buy, 1 hold, 0 sell).

AI Auto Pilots
Is IMCR in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$429.3M
+13.1% vs a year ago
Net income
−$32.1M
−7.5% margin
EPS (diluted)
−$0.64
Free cash flow
−$18.2M
−4.2% margin
Valuation
Market cap
$1.4B
51.7M shares
P/E
–
No P/E while losing money
Price to sales
3.3
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$512.2M
At Sep 30
Shareholder equity
$419.7M
Shares outstanding
51.7M
At Oct 31
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $4.1M$4.1MFY2021FY2022: $174.4M$174.4MFY2022FY2023: $249.4M$249.4MFY2023FY2024: $310.2M$310.2MFY2024FY2025: $400.0M$400.0MFY2025

From IMCR's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 6). Last 12 months adds up the four latest quarters.

Last report
Nov 6
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Buy
3firms
2 Buy1 Hold0 Sell
Each firm's latest rating on IMCR in the past 90 days
Average 12-month target
$57.33
▲ 106.2% upside

Based on 3 analysts who set a price target on IMCR in the past 90 days. The average target is $57.33, with a high of $80.00 and a low of $42.00, compared with the last close of $27.81.

Low $42.00Avg $57.33High $80.00
Blue marker: last close $27.81
Highest target$80.00
Average target$57.33
Lowest target$42.00
Latest rating changes
Morgan StanleyMaintained
Nov 13Hold$42
HC Wainwright & Co.Maintained
Nov 10Buy$80
JP MorganReinstated
Aug 21Buy$50
MizuhoMaintained
Aug 3Hold$35
JefferiesDowngrade
Mar 16Hold$33
DateFirmActionRatingPrice target
Nov 13Morgan StanleyMaintainedHold$42
Nov 10HC Wainwright & Co.MaintainedBuy$80
Aug 21JP MorganReinstatedBuy$50
Aug 3MizuhoMaintainedHold$35
Mar 16JefferiesDowngradeHold$33
Loading…

Technical Analysis

IMCR · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 10% below its 20 day and 11% below its 50 day average. It is 13% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 38), near oversold. The nearest support is the swing low (Jun 11) at $27.59, and the nearest resistance the Pivot at $28.04.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 5.3%/day
Key levels
$40.7152 week high+46.4%
$32.66100 day average+17.4%
$31.54200 day average+13.4%
$30.7750 day average+10.6%
$30.7120 day average+10.4%
$29.54Swing high (Jun 12)+6.2%
$28.76Pivot R1+3.4%
$28.04Pivot+0.8%
$27.81Last close
$27.59Swing low (Jun 11)−0.8%
$27.3252 week low−1.8%
$27.09Pivot S1−2.6%
Indicators
RSI (14)37.61Weak, oversold below 30Neutral
MACD-0.42Below its signal lineBearish
Stochastic21.8Middle of its rangeNeutral
ADX (14)16.3No clear trend
Williams %R-90.7Oversold below −80, overbought above −20Oversold
CCI (20)-187.9Oversold below −100, overbought above 100Oversold
Rate of change−7.4%Change over 10 sessionsBearish
ATR (14)$1.46Typical daily range, 5.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for IMCR

What happened before

See how IMCR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow IMCR usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How IMCR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in IMCR in the last 90 days.

Loading…

See today’s whale options flow across the market →

IMCR Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲72 buying vs 62 selling
  • ▲Held by funds +4.5 pts
  • ▼Funds holding -5
  • ▼Superinvestors: 2 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding133138−3.6%
In funds' top 1052+150.0%
Held by funds106.1%101.6%+4.5 pts
New / increased17 / 5527 / 52−8.9%
Reduced / sold out41 / 2139 / 34−15.1%
Put/call ratio0.992.88−65.7%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See IMCR institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IMCR is in one of them and how their past IMCR trades turned out.

IMCR in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered IMCR in an article yet. Here's the latest on the wider market.

About Immunocore Holdings

Immunocore is a biological products company based in Oxfordshire, United Kingdom. It develops product candidates built on its ImmTAX platform, which it relies on as its core proprietary know-how. Its work involves collaborations with corporate partners, outside scientific collaborators and contract research organizations. Most of its product candidates are still in development and not yet sold to customers.

Headquarters
Oxfordshire, United Kingdom